Aemetis (NASDAQ:AMTX) Share Price Passes Below 200 Day Moving Average of $3.96

Shares of Aemetis, Inc. (NASDAQ:AMTX) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.96 and traded as low as $2.95. Aemetis shares last traded at $3.01, with a volume of 5,571,310 shares trading hands.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AMTX. StockNews.com upgraded Aemetis to a “sell” rating in a research report on Monday, June 3rd. Truist Financial reaffirmed a “hold” rating and issued a $4.00 target price (up from $3.50) on shares of Aemetis in a research report on Monday, May 13th. Finally, HC Wainwright reissued a “buy” rating and set a $28.00 price target on shares of Aemetis in a report on Friday, May 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $12.25.

Aemetis Stock Performance

The business has a fifty day moving average of $3.55 and a 200-day moving average of $3.96. The firm has a market capitalization of $133.64 million, a P/E ratio of -2.57 and a beta of 1.23.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings results on Thursday, May 9th. The specialty chemicals company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.15). The firm had revenue of $72.63 million during the quarter, compared to the consensus estimate of $78.74 million. On average, equities research analysts forecast that Aemetis, Inc. will post -1.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Aemetis

In other news, Director John R. Block sold 51,580 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $3.49, for a total value of $180,014.20. Following the completion of the sale, the director now directly owns 14,001 shares of the company’s stock, valued at approximately $48,863.49. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.34% of the stock is owned by corporate insiders.

Institutional Trading of Aemetis

Institutional investors have recently modified their holdings of the company. Stifel Financial Corp grew its holdings in Aemetis by 58.0% during the third quarter. Stifel Financial Corp now owns 691,445 shares of the specialty chemicals company’s stock worth $2,870,000 after acquiring an additional 253,745 shares during the period. Citigroup Inc. grew its stake in shares of Aemetis by 10,391.3% in the 3rd quarter. Citigroup Inc. now owns 75,013 shares of the specialty chemicals company’s stock worth $311,000 after purchasing an additional 74,298 shares during the last quarter. Barclays PLC bought a new stake in shares of Aemetis in the 3rd quarter worth approximately $150,000. State Board of Administration of Florida Retirement System acquired a new stake in Aemetis during the first quarter valued at approximately $84,000. Finally, SG Americas Securities LLC bought a new stake in Aemetis during the first quarter worth approximately $60,000. Institutional investors and hedge funds own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.